摘要
目的：对恶性肿瘤患者的β2-微球蛋白（β2-MG）、癌胚抗原（CEA）及D-二聚体（D—Dimer）的变化进行研究，并探讨联合检测的临床意义。方法：选取2014年至2015年本院收治的245例恶性肿瘤患者（癌症组）的血清β2-MG、CEA及D-Dimer含量与200例健康对照组进行分析比较。结果：与健康对照组比较，癌症组的血清β2-MG、CEA及D-Dimer含量均明显增高，三者联合检测阳性率高于单一项目检测（P〈0．05）。结论：血清β2-MG、CEA及D-Dimer联合检测对恶性肿瘤患者的早期筛查诊断具有重要的临床价值。
Objective： The changes of β2-microglobulin （β2-MG） , carcino-embryonic antigen （CEA） and D- Dimer in patients with malignant tumor were detected, and the clinical significance of combined detection was discussed. Methods： The levels of serum β2-MG, CEA, and D-Dimer in 245 patients with malignant tumor （cancer group） from 2014 to 2015 were analyzed and compared with the 200 cases of healthy control group. Results： Compared with the healthy control group, the serum levels of β2-MG, CEA and D-Dimer in cancer group were significantly higher, and the positive rate of the three joint detection was higher than that of single item （P〈0.05） . Conclusion： The combined detection of serum β2-MG, CEA and D-Dimer has important clinical value for early screening and diagnosis of malignant tumor patients.
出处
《医学检验与临床》
2016年第9期19-20,47,共3页
Medical Laboratory Science and Clinics
